Synthesis and reactions of 2-hydroxy-5,5-dimethyl- and 2-hydroxy-5,5-pentamethylene-2-trifluoromethyltetrahydro-4-pyranones withN-nucleophiles
作者:V. Ya. Sosnovskikh、M. Yu. Mel'nikov、A. V. Zaitsev、E. A. Bogdanov
DOI:10.1007/bf02503492
日期:1998.6
Condensation of 4-hydroxy-3,3-dimethyl- and 4-hydroxy-3,3-pentamethylenebutan-2-ones with ethyl trifluoroacetate in the presence of LiH in hexane afforded 2-hydroxy-5,5-dimethyl- and 2-hydroxy-5,5-pentamethylene-2-trifluoromethyltetrahydro-4-pyranones, whose behavior in reactions with N-nucleophiles is analogous to that of unsymmetrical polyfluorinated beta-diketones.
HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies
申请人:University of Iowa Research Foundation
公开号:US20180209956A1
公开(公告)日:2018-07-26
Disclosed are methods, compositions, kits, and systems for identifying small-molecule drugs for treating cancer in a subject. The disclosed methods, compositions, kits, and systems may be utilized to identify small-molecule inhibitors of radiation sensitive protein 52 (RAD52) in order to treat cancer in a subject, such as breast cancer in a subject having a BRCA1-deficient, BRCA2-deficient, and/or PALB2-deficient phenotype by administering the identified small-molecule inhibitors to the subject.
[EN] HIGH THROUGHPUT SCREENING ASSAY FOR IDENTIFYING INHIBITORS OF RAD52 AND USES OF THE IDENTIFIED INHIBITORS FOR TREATMENT AND/OR PREVENTION OF MALIGNACIES<br/>[FR] ESSAI DE CRIBLAGE À HAUT DÉBIT PERMETTANT D'IDENTIFIER DES INHIBITEURS DE RAD52 ET UTILISATIONS DES INHIBITEURS IDENTIFIÉS POUR LE TRAITEMENT ET/OU LA PRÉVENTION DES MALIGNITÉS
申请人:UNIV IOWA RES FOUND
公开号:WO2017015187A1
公开(公告)日:2017-01-26
Disclosed are methods, compositions, kits, and systems for identifying small- molecule drugs for treating cancer in a subject. The disclosed methods, compositions, kits, and systems may be utilized to identify small-molecule inhibitors of radiation sensitive protein 52 (RAD52) in order to treat cancer in a subject, such as breast cancer in a subject having a BRCA1- deficient, BRCA2 -deficient, and/or PALB2 -deficient phenotype by administering the identified small-molecule inhibitors to the subject.
Sosnovskikh; Mel'nikov, Russian Journal of Organic Chemistry, 1998, vol. 34, # 2, p. 276 - 279
作者:Sosnovskikh、Mel'nikov
DOI:——
日期:——
Sosnovskih; Mel'nikov, Russian Journal of Organic Chemistry, 1998, vol. 34, # 2, p. 175 - 177